Roche Holding AG Ordinary Shares new Financials - Benzinga

Roche Holding AG Ordinary Shares new

RHHVFOTC

Trade with Public

Trade with Public

$430.78

6.031.42%

At close: Sep 11, 5:00 PM EST

Overview NewsFinancialsSentiment Compare

Roche Holding AG Ordinary Shares new Financials

Roche Holding AG Ordinary Shares new (RHHVF) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Roche Guides To Mid Single-Digit Sales Growth And High Single-Digit Core EPS Expansion In 2026

Roche expects an increase in Group sales in the mid single digit range (CER) for 2026. Core earnings per share are targeted to develop in the high single digit range (CER). Roche expects to further increase its dividend

Benzinga Newsdesk

PRO
Roche Group Sales Rise 7% YoY To CHF 61.516B ($76.963B) At Constant Exchange Rates And Core EPS Grows 11% To CHF 19.46 ($24.35)

Key figuresCHF millions% changeJanuary–December20252024At CER1In CHFGroup sales61,51660,49572Pharmaceuticals Division47,66946,17193Diagnostics Division13,84714,3242-3Core operating profit21,83320,823135Core EPS – diluted

Benzinga Newsdesk

PRO
Roche H1 2025 Sales CHF 30.944B Up From CHF 29.848B YoY, Core EPS CHF 11.08 Up From CHF 10.23 YoY

Group sales grew by 7%1 at constant exchange rates (CER; 4% in CHF), driven by strong demand for medicines.Pharmaceuticals Division sales rose by 10% (6% in CHF), with Phesgo (breast cancer), Xolair (food allergies),

Benzinga Newsdesk

PRO
Roche For 2025 Expects Mid-Single-Digit Sales Growth And High-Single-Digit Core EPS Growth

For 2025, the company expects mid-single-digit sales growth and high-single-digit core EPS growth, with a further increase in dividends in Swiss francs.

Benzinga Newsdesk

PRO
Roche's Q4 Adj. EPS CHF18.80 Up From CHF18.57 YoY, Sales CHF60.49B Up From CHF58.72B YoY

Benzinga Newsdesk

PRO
Roche Holding H1 Adj. EPS CHF 10.23 Up From CHF 10.10 YoY, Revenue CHF 29.85B Up From CHF 29.78B YoY

Benzinga Newsdesk